IgG4相关硬化性胆管炎的临床特征、治疗反应与结局
日本211家转诊中心2000至2015年回顾性纳入527例IgG4-SC患者(女性436例,中位年龄66.2岁),随访中位4.1±3.1年;初诊黄疸35%、瘙痒13%、无症状28%,血清IgG4升高者84%,泼尼松龙治疗反应良好者90%,胆管再狭窄19%但不影响总生存,仅4例(0.7%)发生胆管癌。
要点
- IgG4-SC初诊以黄疸(35%)和瘙痒(13%)多见,28%无症状,失代偿期肝硬化表现极罕见。
- 血清IgG4>135 mg/dL者占84%,泼尼松龙治疗反应良好者达90%。
- 随访中胆管再狭窄19%但不影响总生存,胆管癌仅0.7%,无肝移植。
核心结论
- 日本527例IgG4-SC回顾性队列显示该病呈良性病程,90%患者对泼尼松龙治疗有反应,少数进展为失代偿期肝硬化或胆管癌。
研究设计与样本
- 日本211家转诊中心2000至2015年回顾性队列研究,纳入527例按日本胆道学会2012年临床诊断标准诊断的IgG4-SC患者(女性436例,中位年龄66.2岁,范围23-89岁),随访中位4.1±3.1年。
主要发现
- 初诊症状包括黄疸(35%)、瘙痒(13%),28%无症状,失代偿期肝硬化表现极罕见。
- 初诊时血清IgG4>135 mg/dL者占84%。
- 泼尼松龙治疗反应良好者占90%。
- 随访期间无患者接受肝移植,胆管癌仅4例(0.7%)。
- 胆管再狭窄见于19%患者,但未影响总生存。
关键数值与推荐
- 诊断依据日本胆道学会2012年制定的临床诊断标准。
- 血清IgG4升高定义为>135 mg/dL,84%患者初诊时符合。
- 泼尼松龙治疗反应良好定义为90%患者达到良好反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immunoglobulin G4 sclerosing cholangitis (IgG4-SC) is a biliary tract manifestation of IgG4-related systemic disease. We investigated the demographics, clinical features at presentation, treatment response, and outcomes of IgG4-SC using data from a large-scale survey in Japan. METHODS: We performed a retrospective cohort study of 527 patients with IgG4-SC (436 female; median age, 66.2 years; range, 23-89 years) in Japan from 2000 to 2015. Data on patient demographics, presentation, treatment response, and outcomes were collected from questionnaires given to patients at 211 referral centers in Japan in 2015. Patients were diagnosed with IgG4-SC based on the clinical diagnostic criteria established by the Japanese Biliary Association in 2012. Patients were followed for a median of 4.1 ± 3.1 years. Survival was assessed using the Kaplan-Meier curve and log-rank test. RESULTS: Symptoms at presentation included jaundice (35% of patients) and pruritus (13% of patients); 28% of patients were asymptomatic. It was extremely rare for patients with IgG4-SC to present with symptoms of decompensated cirrhosis. At presentation, serum levels of IgG4 were increased (>135 mg/dL) in 84% of patients. Response to prednisolone was excellent in 90% of patients. No patients received liver transplants, and cholangiocarcinoma was found in only 4 patients (0.7%). Restenosis of bile ducts was observed in 19% of patients but did not affect overall survival. CONCLUSIONS: In a retrospective cohort study of 527 patients with IgG4-SC in Japan, we found the disease to be benign. Most patients (90%) respond to treatment with prednisolone and few develop decompensated cirrhosis or cholangiocarcinoma.
引用
- Tanaka A, Tazuma S, Okazaki K, et al. Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2017. PMID: 28111336. doi:10.1016/j.cgh.2016.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。